ICAM1 and thyroid gland undifferentiated (anaplastic) carcinoma: Furthermore, adoptive transfer of ICAM-1 CAR T cells has been proven safe and feasible in a recent Phase I clinical trial for patients with relapsed/refractory poorly differentiated and anaplastic thyroid cancers [23].